CSNK1A1 and glioblastoma: IC261 is a selective, ATP-competitive CK1 inhibitor that has shown its high efficiency in handling CRC and glioblastoma cells.352,353 Not only that, IC261 has alternatively biological effects that may lead to the death of cancer cells independent of inhibiting the canonical Wnt pathway.352,354 In an in vitro study, IC261 induced centrosome fragmentation during mitosis independent of CK1δ.355 Other CK1 inhibitors include PF670 and PF480 that do not kill cancer cells.